NEUP (Neuphoria Therapeutics) Insider Ownership: 0.19 % (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEUP Neuphoria Therapeutics Inc NEUP
26 GF Score
Price $3.76
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Insider Ownership?

Neuphoria Therapeutics NEUP -2.34% 26 Insider Ownership is 0.19 % as of Aug. 29, 2026. GuruFocus rates NEUP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neuphoria Therapeutics's insider ownership is 0.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neuphoria Therapeutics's Institutional Ownership is 32.53%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neuphoria Therapeutics's Float Percentage Of Total Shares Outstanding is 99.89%.

Neuphoria Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Insider Ownership Chart

Neuphoria Therapeutics Historical Data

The historical data trend for Neuphoria Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19
NEUP
26GF Score
Neuphoria Therapeutics Inc NEUP
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.19 % mean?
Neuphoria Therapeutics (NEUP) has a Insider Ownership of 0.19 % as of Aug. 29, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Insider Ownership too high?
Neuphoria Therapeutics' current Insider Ownership is 0.19 %. Overall, Neuphoria Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Insider Ownership compare to DARE and CLRB?
Neuphoria Therapeutics' Insider Ownership of 0.19 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Insider Ownership is 0.19 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Insider Ownership of 0.19 %. The current Insider Ownership is 0.19 %. Neuphoria Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Insider Ownership is 0.19 % as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
26GF Score

Get the complete analysis for NEUP

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.76
Price